12:00 AM
 | 
Sep 01, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IMC-A12: Phase II started

ImClone began an open-label, U.S. Phase II trial to evaluate weekly 6 mg/kg doses of intravenous IMC-A12 or IMC-1121B in combination with mitoxantrone every...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >